aTyr Pharma Inc.

223 articles with aTyr Pharma Inc.

• aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

  12/24/2021

  aTyr Pharma, Inc. today announced the appointment of Danielle Campbell to Vice President, Human Resources.

• aTyr Pharma to Present at Antibody Engineering & Therapeutics ConferenceNovel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform.

  12/10/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a presentation at the Antibody Engineering & Therapeutics Conference which is being held December 12 – 16, 2021 in San Diego, CA, and virtually.

• aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923

  11/30/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), and FUJIFILM Diosynth Biotechnologies, today announced a manufacturing agreement for ATYR1923, aTyr Pharma’s lead therapeutic candidate that is currently in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

• aTyr Pharma to Present at Upcoming Investor Conferences in November 2021

  11/12/2021

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming virtual investor conferences in November.

• aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

  11/10/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced third quarter 2021 results and provided a corporate update.

• aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial ResultsManagement to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST

  11/3/2021

  aTyr Pharma, Inc. today announced that it will report third quarter 2021 financial results and provide a corporate update after the market close on Wednesday, November 10, 2021.

• aTyr Pharma to Participate in Piper Sandler Investor Lung Day

  10/11/2021

  aTyr Pharma, Inc. today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler Virtual Investor Day: Developing Therapeutics for Lung Indications on Friday, October 15, 2021, at 9:00am ET / 6:00am PT.

• 

  BioSpace Movers & Shakers, Oct. 8

  10/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs

  10/6/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Robert W. Ashworth, Ph.D., to Vice President, Regulatory Affairs.

• aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting

  10/1/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting,

• 

  Clinical Catch-Up: September 13-17

  9/20/2021

  With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.

• aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  9/20/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the closing of an underwritten public offering of 10,781,250 shares of its common stock at a public offering price of $8.00 per share, which included the full exercise of the underwriters’ option to purchase additional shares.

• aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

  9/16/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit,

• aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock

  9/16/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the pricing of an underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00 per share.

• aTyr Pharma Announces Proposed Public Offering of Common Stock - Sep 15, 2021

  9/15/2021

  aTyr Pharma, Inc., a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that it has commenced an underwritten public offering of shares of its common stock.

• aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis

  9/13/2021

  aTyr Pharma, Inc. today announced positive results from its Phase 1b/2a double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923

• aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University

  8/10/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company, today announced that the company has expanded its research collaboration with The Ohio State University (OSU) to deepen the understanding of the immune mechanisms of sarcoid granuloma formation and identify potential biomarkers of efficacy for the company’s lead therapeutic candidate, ATYR1923, which is currently in clinical development for the treatment of pulmonary sarcoidosis.

• aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress

  8/9/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company’s lead therapeutic candidate, ATYR1923, have been accepted for presentation at the 2021 European Respiratory Society International Congress to be held virtually September 5 – 8.

• aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

  8/3/2021

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that it will report second quarter 2021 financial results and provide a corporate update after the market close on Tuesday, August 10, 2021.

• aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

  7/29/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering methods for the use of histidyl-tRNA synthetase Fc fusion proteins for reducing inflammatory response in the lung.